Spots Global Cancer Trial Database for Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer
Official Title: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer
Study ID: NCT05766748
Conditions
Interventions
Study Description
Brief Summary: This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line or second-line treatment of metastatic pancreatic cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton, Florida, United States
Williamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
AHN Cancer Institute - Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Prisma Health - Upstate, Greenville, South Carolina, United States
Texas Oncology - Northeast Texas, Tyler, Texas, United States
Contact Details
Name: Andrew Hendifar, MD
Affiliation: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
